-
公开(公告)号：US20220304956A1
公开(公告)日：2022-09-29
申请号：US17665894
申请日：2022-02-07
申请人： Epitech Group S.p.A.
发明人： Francesco DELLA VALLE , Maria Federica DELLA VALLE , Gabriele MARCOLONGO , Giuliano CLAPS , Chiara GOMIERO , Vito SAFINA , Annalisa NOCE , Salvatore CUZZOCREA , Giuseppe ESPOSITO
摘要： The present invention relates to a method of treating a COVID-19 infection by administering an effective amount of an endogenous compound devoid of significant toxicity. In particular, the present invention relates to a method of treating a patient affected by COVID-19 infection comprising administering an effective amount of a mixture of ultra-micronized palmitoylethanolamide and micronized palmitoylethanolamide to said patient.
-
公开(公告)号：US12102608B2
公开(公告)日：2024-10-01
申请号：US17825260
申请日：2022-05-26
申请人： EPITECH GROUP S.P.A.
IPC分类号： A61K31/164 , A23L33/115
CPC分类号： A61K31/164 , A23L33/115
摘要： A composition of acylethanolamides is obtained from olive oil fatty acids and is used in treating neuroinflammation. The acylethanolamide complex includes (weight percentages):
oleoylethanolamide (OEA) C18:1
60-65%
palmitoylethanolamide (PEA) C16:0
5-20%
linoleylethanolamide (LEA) C18:2
5-20%
stearoylethanolamide (SEA) C18:0
1-2%
palmitoylethanolamide (POEA) C16:1
0.1-0.8%
myristoylethanolamide (MEA) C14:0
0.02-0.15%
mixture of glycerides
4-6%
glycerol
6-8%.
A method obtains the acylethanolamide complex and formulations contain the acylethanolamide complex.-
公开(公告)号：US11491122B2
公开(公告)日：2022-11-08
申请号：US16374912
申请日：2019-04-04
申请人： Epitech Group S.p.A.
发明人： Maria Federica Della Valle , Francesco Della Valle , Vincenzo Di Marzo , Stefania Petrosino , Barbara Costa , Gabriele Marcolongo , Daniele Grassi
IPC分类号： A61K31/16 , A61K45/06 , A61K31/164 , A61K31/201 , A61K31/421 , A61K31/728 , A61K36/062 , A61K36/28
摘要： Described herein is the use of Adelmidrol in the treatment of epithelial dysfunctions. In particular, described herein is Adelmidrol for use in the treatment of epithelial tissue dysfunctions in a human being or animal, wherein said Adelmidrol causes an increase of the endogenous levels of Palmitoylethanolamide without inhibiting the activity of the Palmitoylethanolamide-degrading FAAH and NAAA enzymes.
-
公开(公告)号：US11819511B2
公开(公告)日：2023-11-21
申请号：US17002073
申请日：2020-08-25
申请人： EPITECH GROUP S.P.A
发明人： Francesco Della Valle , Maria Federica Della Valle , Gabriele Marcolongo , Salvatore Cuzzocrea , Vito Safina
摘要： Described herein is a composition based on N-palmitoyl-ethanolamide and Rutin in co-micronized form. In particular, a composition includes a mixture of palmitoyl-ethanolamide (PEA) and Rutin in co-micronized form in which the PEA/Rutin ratio is between 10:1 and 1:1. Pharmaceutical formulations for the treatment of humans and animals are also described. The composition is useable for the treatment of diseases of arteries and arterioles.
-
公开(公告)号：US20230285349A1
公开(公告)日：2023-09-14
申请号：US18184797
申请日：2023-03-16
申请人： EPITECH GROUP S.P.A.
IPC分类号： A61K31/221 , A61K9/16 , A61K9/00 , A61K31/7034 , A61K31/164
CPC分类号： A61K31/221 , A61K9/1647 , A61K9/0024 , A61K31/7034 , A61K31/164
摘要： It is the object of the present invention a pharmaceutical composition for use in humans or animals containing N-palmitoylethanolamide for the control of the inflammatory and/or neuropathic pain of various origin. In particular, the present invention relates to a pharmaceutical composition comprising palmitoylethanolamide (PEA and L-acetylcarnitine (LAC), optionally with in addition an antioxidant compound such as a polyphenol, alpha-lipoic acid, and L-acetylcysteine.
-
公开(公告)号：US20210060047A1
公开(公告)日：2021-03-04
申请号：US17002073
申请日：2020-08-25
申请人： EPITECH GROUP S.P.A
发明人： Francesco DELLA VALLE , Maria Federica DELLA VALLE , Gabriele MARCOLONGO , Salvatore CUZZOCREA , Vito SAFINA
摘要： Described herein is a composition based on N-palmitoyl-ethanolamide and Rutin in co-micronized form. In particular, a composition includes a mixture of palmitoyl-ethanolamide (PEA) and Rutin in co-micronized form in which the PEA/Rutin ratio is between 10:1 and 1:1. Pharmaceutical formulations for the treatment of humans and animals are also described. The composition is useable for the treatment of diseases of arteries and arterioles.
-
公开(公告)号：US20190290609A1
公开(公告)日：2019-09-26
申请号：US16436143
申请日：2019-06-10
申请人： EPITECH GROUP S.P.A.
IPC分类号： A61K31/221 , A61K9/16 , A61K31/164 , A61K31/7034 , A61K9/00
摘要： It is the object of the present invention a pharmaceutical composition for use in humans or animals containing N-palmitoylethanolamide for the control of the inflammatory and/or neuropathic pain of various origin. In particular, the present invention relates to a pharmaceutical composition comprising palmitoylethanolamide (PEA and L-acetylcarnitine (LAC), optionally with in addition an antioxidant compound such as a polyphenol, alpha-lipoic acid, and L-acetylcysteine.
-
公开(公告)号：US20230381121A1
公开(公告)日：2023-11-30
申请号：US18303789
申请日：2023-04-20
申请人： EPITECH GROUP S.P.A.
发明人： Raffaella DELLA VALLE , Maria Federica DELLA VALLE , Gabriele MARCOLONGO , Chiara GOMIERO , Salvatore CUZZOCREA , Antonio CALIGNANO , Claudia CRISTIANO
IPC分类号： A61K31/164 , A61K31/4045 , A61K31/405 , A61P25/00 , A61K9/14
CPC分类号： A61K31/164 , A61K31/4045 , A61K31/405 , A61P25/00 , A61K9/141
摘要： The present invention relates to the use of N-palmitoylethanolamide (PEA) in association with melatonin or natural precursors thereof in the treatment of autism spectrum disorder (ASD) and other neurobehavioral disorders similarly accompanied by restlessness, irritability, sleep disorders, and potentially stereotypies.
In particular, the present invention relates to the use of PEA in association with melatonin in the treatment of ASD, wherein the palmitoylethanolamide is administered in association with melatonin or tryptophan (TRP) or 5-hydroxytriptophan (5H-TRP), wherein said administration is separate, combined or simultaneous.-
公开(公告)号：US20220304954A1
公开(公告)日：2022-09-29
申请号：US17213856
申请日：2021-03-26
申请人： Epitech Group S.p.A.
发明人： Francesco Della Valle , Maria Federica Della Valle , Gabriele Marcolongo , Giuliano Claps , Chiara Gomiero , Vito Safina
摘要： The present invention relates to a method of treating a COVID-19 infection by administering an effective amount of an endogenous compound devoid of significant toxicity. In particular, the present invention relates to a method of treating a patient affected by COVID-19 infection comprising administering an effective amount of a mixture of ultra-micronized palmitoylethanolamide and micronized palmitoylethanolamide to said patient.
-
10.发明公开公开(公告)号：US20240315990A1
公开(公告)日：2024-09-26
申请号：US18736787
申请日：2024-06-07
申请人： Epitech Group S.P.A.
IPC分类号： A61K31/16 , A61K31/164 , A61K31/728
CPC分类号： A61K31/16 , A61K31/164 , A61K31/728
摘要： Described herein are pharmaceutical compositions containing Adelmidrol. In particular, the Adelmidrol is used in the treatment of diseases characterized by insufficient specific agonism of the PPAR-gamma receptor in humans or animals, more particularly in the treatment of articular chondropathies of mechanical, toxic, iatrogenic, degenerative origin, or associated with inflammatory phenomena mainly related to organs and tissues not belonging to the osteoarticular system; fibrogenesis of the articular cartilages; chronic inflammatory bowel diseases (IBDs) such as Crohn's disease and ulcerative colitis; Irritable Bowel Syndrome (IBS); diseases characterized by an abnormal fibrosis of the connective tissue, such as systemic sclerosis, particularly of the skin and lung; eye disorders characterized by angiogenesis, fibrosis, inflammation and oxidative stress.
-
-
-
-
-
-
-
-
-
搜索结果
16 条记录 (耗时 0.016 秒)
